As the New York Times reports, Washington State nurse Jeannette Simonton was told that her insurer has a blanket ban on weight loss meds and would not cover her prescription for Wegovy, the semaglutide injectable thats swept off shelves this year
Smaller, more frequent meals are generally better tolerated than large ones because GLP-1 medications slow gastric emptying
We prioritize these advanced delivery systems because we want our community to see real results, not just expensive waste
Taken together, the available literature provides coherent guidance, interpreting the available data as signaling a possible, but still low certainty, increase in NAION risk with semaglutide, while framing this against the drugs substantial cardiometabolic benefits
& : #DesmopressinMarket #PharmaceuticalIndustry #Biotech #RareDiseases #DrugDevelopment #HealthcareTrends #MarketResearch #LifeSciences #GlobalHealth To view or add a comment, sign in 156 followers Explore related topics Trends in Glp-1 Treatment Options How Glp-1 Drugs Impact Economic Trends Advancements in Diabetes and Obesity Treatments Impact of Patent Expiry on Product Development in India Impact of Glp-1 Medications on Health Market Opportunities After Patent Expiry Innovations in Diabetes Care and Insulin Management Latest Developments in Type 1 Diabetes Research
[MUSIC PLAYING] SPEAKER: Diabetes is a long-lasting and progressive illness that makes it hard for your body to use sugar for energy
